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ABSTRACT
TFIIIC is a RNA polymerase (pol) III-specific DNA-
binding factor that is required for transcription of
tRNA and 5S rRNA genes. Active human TFIIIC
consists of five subunits. However, an inactive form
has also been isolated that lacks one of the five
subunits, called TFIIIC110. A model was proposed in
which pol III transcription might be regulated by the
specific induction of TFIIIC110, allowing formation
of active TFIIIC from the inactive form. We have
tested this model by transient transfection of
HeLa and HEK293 cells with a vector expressing
TFIIIC110. We have also made stably transfected
HeLa cell lines that carry a doxycycline-inducible
version of the cDNA for TFIIIC110. We show that the
induced TFIIIC110 enters the nucleus, binds other
TFIIIC subunits and is recruited to tRNA and 5S
rRNA genes in vivo. However, little or no effect is
seen on the expression of pol III transcripts. The
data argue against the model that pol III transcrip-
tion can be effectively modulated through the
specific induction of TFIIIC110.
INTRODUCTION
TFIIIC is a large DNA-binding factor that directly recognizes
the promoter sequences found within most pol III-transcribed
genes, including tRNA and 7SL RNA genes and the adenovi-
ral VA genes (1–3). It is also required for transcription of 5S
rRNA genes, although in this case its recruitment is depen-
dent on an additional polypeptide called TFIIIA (1–3).
Indeed, it is probable that TFIIIC is used by all pol III tem-
plates in the yeast Saccharomyces cerevisiae, although it is
not necessary for pol III transcription of mammalian U6
and 7SK RNA genes (1–3).
Human TFIIIC has been puriﬁed from HeLa cells as a
complex of ﬁve subunits (4–6). These are commonly referred
to as TFIIIC220, TFIIIC110, TFIIIC102, TFIIIC90 and TFI-
IIC63, according to their approximate molecular masses. An
alternative nomenclature of TFIIICa, b, g, d and e has also
been used (7). The complex is stable, as the subunits remain
associated following immunoprecipitation and washing in
1 M NaCl (8). Cloning of cDNAs for all ﬁve subunits has
allowed conﬁrmation that each is a bona ﬁde component of
TFIIIC (6,8–11). However, the complex has also been puri-
ﬁed with the TFIIIC110 subunit missing (5). Furthermore,
calculations based on metabolic labeling suggested that TFI-
IIC from cycling HeLa cells contains half as much TFIIIC110
as TFIIIC220 (7). TFIIIC complexes with or without the
110 kDa subunit were dubbed TFIIIC2a and TFIIIC2b,
respectively, and shown to be resolved on non-denaturing
gels or by gradient chromatography (5,9,12). Although the
two forms produced identical footprints and had similar
DNA-binding afﬁnities, the complex without TFIIIC110
was unable to support transcription (5,12). These observa-
tions lead to a model in which TFIIIC activity could be regu-
lated by reversible interaction of the TFIIIC110 subunit with
the remainder of the complex (Figure 1). The interaction
might be controlled by phosphorylation, as TFIIIC2b could
be generated by phosphatase treatment of fractions containing
active TFIIIC2a (12). The model was proposed to explain pol
III transcriptional induction observed when HeLa cells are
stimulated with serum or with adenoviral E1A (5,9,12).
The E1A oncoprotein of adenovirus can stimulate pol III
transcription, probably through several complementary
mechanisms (5,9,12–20). Hoefﬂer et al. (12) reported that
the ratio of active TFIIIC2a to inactive TFIIIC2b, as mea-
sured by electrophoretic mobility shift assay (EMSA), is
higher in HeLa cells infected with wild-type adenovirus
than in cells infected with the E1A deletion mutant dl312.
In support of this, western blotting revealed lower levels of
TFIIIC110 following dl312 infection, compared with wild-
type virus (9). EMSA analysis also suggested that the ratio
of TFIIIC2a to TFIIIC2b is elevated in the E1A-transformed
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transformed lines of murine ﬁbroblasts (12,21). Subsequent
studies found that all ﬁve subunits of TFIIIC are overex-
pressed in the SV40-transformed ﬁbroblasts compared to
untransformed parental cells, although the effect appears
strongest for TFIIIC110 (22,23).
The rate of synthesis of pol III products is inﬂuenced
strongly in mammalian cells by serum availability. Hoefﬂer
et al. (12) reported that the relative proportion of TFIIIC2a
to TFIIIC2b was reduced in HeLa cells grown in low
serum, an effect which correlated with the reduced trans-
criptional activity. Consistent with this, western blotting
revealed a decrease in expression of TFIIIC110 under low
serum conditions, whereas TFIIIC220 levels were unchanged
(9). A selective change in TFIIIC110 expression was there-
fore proposed as a mechanism allowing the pol III machinery
to adapt to serum availability.
The model in Figure 1 was based on correlative data—
relatively high ratios of TFIIIC2a to TFIIIC2b and of TFI-
IIC110 to TFIIIC220 seen in transcriptionally active extracts
from cells grown in the presence of E1A or high serum.
However, these observations did not distinguish between
cause and effect. The data are compatible with the possibility
that selective loss of TFIIIC110 might occur as a conse-
quence of down-regulated transcription, rather than having
a causative role. For example, surplus TFIIIC might be
degraded when active transcription is not occurring and
TFIIIC110 might simply be less stable than the other subunits
and therefore removed ﬁrst, allowing accumulation of TFI-
IIC2b. Therefore, we tested the model directly by determin-
ing whether a speciﬁc induction of TFIIIC110 is sufﬁcient
to stimulate pol III transcription.
MATERIALS AND METHODS
Cell culture
HeLa and HEK293 cells were cultured in DMEM supple-
mented with 10% FBS, 100 U/ml penicillin and 100 mg/ml
streptomycin. HeLa TET-ON cells were cultured in 10%
FBS (tetracycline free), 100 U/ml penicillin, 100 mg/ml
streptomycin and 100 mg/ml G418. Stably transfected
HeLa TET-ON cells were also supplemented with
100 mg/ml hygromycin. Expression of HA-TFIIIC110 and
HA-Brf1 was induced by the addition of 1 mg/ml doxycycline
for 48 h.
HeLa cell proliferation assay
Cells were plated on to 75 cm
2 ﬂasks at a density of 5 · 10
5
cells per plate, in media containing 0.5% or 10% FBS. Viable
cells were counted every 24 h using trypan blue staining and
a haemocytometer.
Transient and stable transfection
Transient transfection of HeLa and HEK293 cells were
carried out using Lipofectamine. Stable transfection of
HeLa TET-ON cells were also achieved using Lipofectamine.
Stable transformants were selected using 200 mg/ml
hygromycin.
Plasmids
pVA1 contains the adenovirus VA1 gene (24). pEGFP
(Clontech) contains a cDNA encoding a derivative of green
ﬂuorescent protein expressed from a cytomegalovirus (CMV)
promoter. pTRE2hygHA-Brf1 was produced by PCR ampli-
ﬁcation and sub-cloning into the pTRE2hyg vector (Clon-
tech) the HA-Brf1 coding sequence from pcDNA3HA-Brf1
(25). Human TFIIIC110 was PCR ampliﬁed from the
pRSET-TFIIIC110 vector (a kind gift from Robert Roeder)
and subcloned into pcDNA3HA, generating pcDNA3HA-
TFIIIC110. HA-TFIIIC110 was subsequently subcloned into
pTRE2hyg, again by PCR, to generate pTRE2hygHA-TFI-
IIC110.
Western blotting and antibodies
Cells were washed twice with ice-cold phosphate-buffered
saline (PBS) and scraped into lysis buffer [20 mM HEPES
(pH 7.8), 150 mM NaCl, 25% glycerol, 50 mM NaF,
0.2 mM EDTA, 0.5% Triton X-100, 0.5% NP-40, 10 mM
b-glycerophosphate, 1 mM sodium orthovanadate, 1 mM
phenylmethlysulfonyl ﬂuoride (PMSF), 1 mM DTT, 0.5 mg/ml
leupeptin, 1.0 mg/ml trypsin inhibitor, 0.5 mg/ml aprotinin and
40 mg/ml bestatin]. Lysates were incubated on ice for 10 min
and passed through a 26-gauge needle three times, before
centrifugation at 16 000 G for 10 min at 4 C. The supernatant
was collected for immunoblot analysis, which was performed
as described previously (26).
Antibodies were F-7 against HA, SI-1 against TFIIB, C11
against actin and R-124 against cyclin D1 from Santa Cruz
Biotechnologies. The Rb antibody G3-245 was from BD
Pharmingen. Peptide antisera 128 against Brf, Ab4 against
TFIIIC220, MTBP-6 against TBP and 1898 against TFIIIC90
have been described previously (7,23,25,27,28). Antibody
3208 against TFIIIC110 was raised by immunizing rabbits
with synthetic peptide GEAGPVGNMTVVDSP (human
TFIIIC110 residues 12–26) coupled to keyhole limpet
haemocyanin.
Immunoprecipitation
Whole cell extracts (150 mg), prepared as described pre-
viously (26), were incubated in an orbital shaker for 3 h at
4 C with 30 ml of protein G beads carrying equivalent
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Figure 1. Model proposing that an inactive form of TFIIIC, called TFIIIC2b,
is converted to an active form, called TFIIIC2a, by the selective induction of
TFIIIC110 in response to serum or E1A. Both forms bind to promoter DNA,
but only TFIIIC2a is competent to support transcription.
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beads washed ﬁve times with PBS. The bound material was
analysed by western blotting.
Primer extension
Total RNA was extracted using TRI reagent, according to
manufacturers’ instructions. RNA was then analysed by
primer extension using labelled primers speciﬁc for VA1
50-CACGCGGGCGGTAACCGCATG-30 and green ﬂuores-
cent protein (GFP) 50-CGTCGCCGTCCAGCTCGACCAG-
30. Primer extension assays were performed as described
previously (20).
RT–PCR
RT–PCR analysis of ARPP P0 mRNA, 5S rRNA and tRNA
transcripts were performed as described previously (29,30).
Northern blotting
Northern blotting was carried out as described previously
(28). The ARPP P0 probe was a 1 kb EcoRI–HindIII frag-
ment from the mouse cDNA (31). The tRNA probe was a
240 bp EcoRI–HindIII fragment from pLeu (32).
Immunofluorescence microscopy
Cells on coverslips were ﬁxed in 4% para-formaldehyde in
PBS for 10 min, followed by permeabilization in 0.1% Triton
X-100 in PBS for 4 min. Cells were washed, blocked in 0.1%
goat serum and 0.2% ﬁsh skin gelatin in PBS, before incuba-
tion with primary antibody (HA from Santa Cruz) at 1:100 or
1:500 dilution. Cells were again washed and blocked fol-
lowed by incubation with secondary antibody (Alexa Fluor
488 goat anti-mouse IgG, from Molecular Probes) at 1:400
dilution. Cells were washed with PBS and mounted on to
glass slides and viewed using a Zeiss Axiovert ﬂuorescence
microscope.
Chromatin immunoprecipitation (ChIP)
ChIP assays were carried out as described (33). The antibod-
ies used were MTBP-6 against TBP (27), 4286 against
TFIIIC110 (25), F-7 against HA and SI-1 against TFIIB
(both from Santa Cruz Biotechnologies). Primers and cycling
parameters were as described previously (29,33). Serial dilu-
tions of chromatin were used to conﬁrm PCRs were within a
linear range.
RESULTS
Transient transfection of a TFIIIC110 expression vector
has minimal effect on pol III transcription in
HeLa and HEK293 cells
A mammalian expression vector was constructed that
allows overexpression of an mRNA encoding HA-tagged
TFIIIC110. This construct was transiently transfected into
HEK293 cells along with the adenoviral VA1 gene, the pol
III-transcribed gene used in the original studies by Hoefﬂer,
Kovelman and Roeder (5,12). A vector encoding GFP
transcribed from the CMV promoter was cotransfected as a
control for transfection efﬁciency. Western blotting for the
HA tag conﬁrmed that the exogenous TFIIIC110 protein
was expressed in the transfected cells (Figure 2A). However,
little or no effect was seen in multiple experiments on the
level of VA1 transcript, as assayed by primer extension
(Figure 2B and C).
The lack of response in HEK293 cells might be explained
by the fact that this line expresses E1A, which was reported
to elevate TFIIIC110 expression; the ratio of this polypeptide
with respect to other TFIIIC subunits may already be high
in these cells, such that TFIIIC2a predominates (12). There-
fore, we repeated the experiment in HeLa cells, which were
reported to have a signiﬁcant fraction of TFIIIC2b, which
lacks the TFIIIC110 subunit. In contrast to HEK293 cells, a
modest, dose-dependent induction of VA1 RNA was observed
when the HA-TFIIIC110 expression vector was transfected
into HeLa cells (Figure 3A and B). After normalization to
the cotransfected GFP internal control, the average response
was  1.5-fold (Figure 3C).
RT–PCR analysis was used to determine if levels of the
endogenous pol III transcripts are inﬂuenced by transient
Figure 2. Transient transfection of a HA-TFIIIC110 expression vector has
little or no effect on VA1 transcript levels in HEK293 cells. (A) Western blot
of HEK293 cells transfected with pcDNA3HA-TFIIIC110 and/or pcDNA3-
HA to a total concentration of 2 mg. Upper panel shows a blot for HA-
TFIIIC110, lower panel shows a blot for actin. (B) Primer extension analysis
of VA1 and GFP RNA in HEK293 cells transfected with 0.25 mg of each of
the VA1 and GFP plasmids and with pcDNA3HA-TFIIIC110 and/or
pcDNA3HA to a total concentration of 2 mg. (C) Quantitation of the data
from (B) and three identical experiments.
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expression of 5S rRNA and tRNA genes, both of which
require TFIIIC for their transcription (1–3). No reproducible
induction was observed for 5S rRNA, whereas tRNA showed
a slight response of  1.5-fold (Figure 3D and E). Although,
this assay measures the steady-state level of 5S rRNA, our
tRNA primers are speciﬁc for short-lived primary transcripts,
which are considered to reﬂect the rate of ongoing transcrip-
tion (29). This approach therefore provided limited support
for the model that class III gene expression can be stimulated
by a speciﬁc increase in the ratio of TFIIIC110 to other
TFIIIC subunits.
Stable induction of TFIIIC110 in HeLa cells has little
effect on expression of tRNA and 5S rRNA
The experiments in Figure 3D and E measured levels of
endogenous transcripts in the total cell population. However,
Figure 3. Transient transfection of a HA-TFIIIC110 expression vector has only a minor effect on VA1 reporter or endogenous pol III transcript expression in
HeLa cells. (A) Western blots of HeLa cells transfected with pcDNA3HA-TFIIIC110 and/or pcDNA3HA to a total concentration of 2 mg. Upper panel shows a
blot for HA-TFIIIC110, lower panel shows a blot for actin. (B) Primer extension analysis of VA1 and GFP RNA in HeLa cells transfected with 0.25 mg of each of
the VA1 and GFP plasmids and with pcDNA3HA-TFIIIC110 and/or pcDNA3HA to a total concentration of 2 mg. Note that lane 3 is somewhat overloaded.
(C) Quantitation of the data from Figure 3B and three additional experiments. (D) RT–PCR analysis of 5S rRNA, tRNA and ARPP P0 mRNA, as indicated, in
HeLa cells transfected with pcDNA3HA-TFIIIC110 and/or pcDNA3HA to a total concentration of 2 mg. (E) Quantitation of the data from (D) and three
additional experiments.
3402 Nucleic Acids Research, 2006, Vol. 34, No. 11immunoﬂuorescence analysis of GFP expression from the
cotransfected control vector indicated that many of the HeLa
cells remain untransfected under the conditions of our assays
(data not shown). Since the presence of untransfected cells
may partially mask a response, we produced HeLa cell clones
that were stably transfected in the presence of a selectable
marker, to ensure that the entire population receives the
expression vector. The TFIIIC110 cDNA was subcloned
into pTRE2hyg, which carries a doxycycline-responsive pro-
moter. This was then used to produce multiple clones in
which HA-tagged TFIIIC110 can be induced speciﬁcally by
addition of doxycycline to the culture medium. Individual
clones varied considerably in the levels of HA-TFIIIC110
that were produced (Figure 4A). We also observed clonal
variation in the expression of tRNA and 5S rRNA
(Figure 4B). However, RT–PCR analysis revealed no consis-
tent change in the expression of pol III transcripts following
induction of HA-TFIIIC110 (Figure 4B and C).
The model in Figure 1 predicts that pol III transcription
might be more sensitive to TFIIIC110 induction under low
serum conditions. Therefore, we cultured HeLa cells in
0.5% serum, as in the previous work (9,12). This treatment
was sufﬁcient to cause a marked reduction in cell prolifera-
tion (Figure 5A). Trypan blue staining did not reveal any sub-
stantial apoptosis (data not shown). As expected (32,34,35),
tRNA expression was markedly diminished in low serum
(Figure 5B). This was accompanied by a slight decrease in
expression of endogenous TFIIIC110, as revealed by western
blotting (Figure 5C). HA-TFIIIC110 remained inducible
under these conditions (Figure 5D), but we again found that
its induction has little or no effect on tRNA or 5S rRNA
levels (Figure 5E and F).
Control experiments were conducted to verify that the
exogenous HA-TFIIIC110 is incorporated into TFIIIC com-
plexes. Sequence analysis using the PSORT II programme
(http://psort.ims.u-tokyo.ac.jp) revealed a strong nuclear
localization signal (NLS) in TFIIIC220, but not in the other
TFIIIC subunits. Unincorporated HA-TFIIIC110 may there-
fore be retained in the cytoplasm. Indeed, cytoplasmic ﬂuo-
rescence was detected with antibody against the HA tag
following addition of doxycycline to the stable transfectants
(Figure 6A). However, an intense immunoﬂuorescence signal
was also observed from the nuclei. This is consistent with the
possibility that although some of the induced protein may
remain unincorporated and hence in the cytoplasm, a signiﬁ-
cant proportion associates with TFIIIC220 to form a complex
that enters the nucleus. Complex assembly is supported by
the ﬁnding that HA-TFIIIC110 can be coimmunoprecipitated
from doxycycline-treated cells using antiserum against
TFIIIC220 (Figure 7A). Other TFIIIC subunits also associate
with the HA-TFIIIC110, as shown by the fact that anti-HA
antibody coimmunoprecipitates TFIIIC90 following doxycy-
cline treatment (Figure 7B). This interaction is speciﬁc,
since TFIIIC90 is not detected after control immunoprecipita-
tions using antibodies against RB or cyclin D1. In addition,
HA-TFIIIC110 is detected by ChIP at chromosomal tRNA
and 5S rRNA genes, but not at the gene encoding TFIIIC220,
which we used as a pol II-transcribed negative control
(Figure 7C). In contrast, the pol II-speciﬁc transcription
factor TFIIB is detected at the TFIIIC220 gene, but not at
tRNA or 5S rRNA genes, as expected. These data conﬁrm
that the doxycycline-induced exogenous HA-TFIIIC110 is
incorporated into TFIIIC complexes that are recruited to
the appropriate target genes in vivo. However, ChIP with an
antibody that recognizes total TFIIIC110 (i.e. both endoge-
nous and HA-tagged forms), shows no increase in gene occu-
pancy in response to doxycycline (Figure 7C, lanes 3 and 4).
The data suggest that although stable transfection with an
inducible construct is able to raise the total level of
TFIIIC110 in HeLa cells, it has little impact on the amount
of this subunit that is assembled onto promoters. This is
consistent with the lack of a signiﬁcant transcriptional
response.
Figure 4. Stable expression of HA-TFIIIC110 has little or no effect
on endogenous pol III transcript levels in actively proliferating HeLa
cells. (A) Western blot of HeLa cell clones stably transfected with
pTRE2hygHA-TFIIIC110 and cultured in 10% serum in the presence or
absence of doxycycline for 48 h. Upper panel shows a blot for HA-
TFIIIC110, lower panel shows a blot for actin. (B) RT–PCR analysis of 5S
rRNA, tRNA and ARPP P0 mRNA, as indicated, in HeLa cells stably
transfected with pTRE2hygHA-TFIIIC110 and grown in 10% serum in the
presence or absence of doxycycline for 48 h. (C) Quantitation of the data
from three independent HeLa cell clones stably transfected with
pTRE2hygHA-TFIIIC110 and grown in 10% serum in the presence or
absence of doxycycline.
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expression of tRNA and 5S rRNA
The data above show that speciﬁc induction of TFIIIC110
in HeLa cells has minimal effect on the expression of endoge-
nous tRNA and 5S rRNA, even though the induced protein
interacts with other TFIIIC subunits and is recruited to the
appropriate template genes. Since this can be viewed as a
negative result, it was necessary to conﬁrm that the system
we have used is amenable to transcriptional induction if a
limiting factor is employed. We chose to try the Brf1 subunit
of TFIIIB, as this has been shown to stimulate tRNA and 5S
rRNA gene transcription when titrated into HeLa cell
extracts. Therefore, we prepared stably transfected HeLa cell
clones that carry doxycycline-inducible HA-tagged Brf1,
using exactly the same approach as described above for
HA-TFIIIC110. Blotting for the HA tag conﬁrmed that
HA-Brf1 can be induced in these cells by the addition of
doxycycline (Figure 8A). A high proportion of this protein
is localized to the nucleus (Figure 6B). Furthermore, RT–
PCR analysis showed that tRNA and 5S rRNA levels are
increased signiﬁcantly in response to induction of HA-Brf1
(Figure 8B and C). This conﬁrms that the doxycycline-
regulated system used in these experiments can be exploited
to activate pol III transcription. Therefore, we infer that a
speciﬁc increase in the level of TFIIIC110 may not be an
effective mechanism for pol III regulation in HeLa cells, as
postulated.
DISCUSSION
In these experiments we have tested directly the model
that TFIIIC110 is ‘a central controlling subunit’ for pol III
Figure 5. Stable expression of HA-TFIIIC110 has little or no effect on endogenous pol III transcript levels in HeLa cells cultured in low serum. (A) Proliferation
curve of HeLa cells cultured for 7 days in media containing 0.5 or 10% serum. (B) Northern blot analysis of total RNA (10 mg) extracted from HeLa cells
cultured for 4 days in media containing 0.5 or 10% serum. The upper panel shows the blot probed with a tRNA
Leu gene and the lower panel shows the same blot,
which has been stripped and re-probed for ARPP P0 mRNA. (C) Western blot of endogenous TFIIIC110 and actin in HeLa cells cultured for 4 days in media
containing 0.5 or 10% serum. (D) Western blot of HeLa cells stably transfected with pTRE2hygHA-TFIIIC110 and cultured in 0.5 or 10% serum in the presence
or absence of doxycycline for 48 h. Upper panel shows a blot for HA-TFIIIC110, lower panel shows a blot for actin. (E) RT–PCR analysis of 5S rRNA, tRNA
and ARPP P0 mRNA, as indicated, in HeLa cells stably transfected with pTRE2hygHA-TFIIIC110 and cultured in 0.5% serum in the presence or absence of
doxycycline for 48 h. (F) Quantitation of the data from three independent HeLa cell clones stably transfected with pTRE2hygHA-TFIIIC110 and cultured in
0.5% serum in the presence or absence of doxycycline.
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previously (9). Our data do not support this idea. A weak
induction by TFIIIC110 was observed for the VA1 and
tRNA genes in transiently transfected cells, but this was
only around 1.5-fold. Furthermore, this small effect was not
reproducible in stably transfected cells. 5S rRNA gene
expression did not respond to TFIIIC110 induction under
either circumstance. In contrast, induction of Brf1 produces
a strong increase in tRNA and 5S rRNA expression under
the same conditions. We have conﬁrmed that the induced
TFIIIC110 can interact with other TFIIIC subunits, enter
the nucleus and be recruited speciﬁcally to target genes.
However, this has little effect on the overall amounts of
TFIIIC110 being recruited to chromosomal genes. The data
suggest that this subunit is not limiting in the contexts we
have investigated.
It was reported that several unidentiﬁed polypeptides
co-puriﬁed with inactive TFIIIC2b and were not associated
with active TFIIIC2a (5,9). In particular, a polypeptide of
77 kDa co-fractionated consistently with TFIIIC2b, although
it was never detected by co-immunoprecipitation (9). As it
was unclear whether this was a contaminant or had functional
signiﬁcance, the model of TFIIIC regulation by differential
interaction with TFIIIC110 included the possibility that
TFIIIC2b might contain an additional 77 kDa subunit as
well as lacking TFIIIC110 (9). As far as we are aware, the
identity of this putative subunit has not been reported.
Clearly, the possibility of its involvement has not been
addressed by our study.
Experiments carried out by Shen et al. lead them to ques-
tion the existence of TFIIIC2b (7). These authors raised an
antiserum against TFIIIC110 that, when used in an EMSA,
was able to block all the DNA-binding activity of TFIIIC
in a HeLa extract (7). This ﬁnding clearly conﬂicts with the
report that a signiﬁcant fraction of HeLa cell TFIIIC exists
in a form (i.e. TFIIIC2b) that lacks TFIIIC110 but is undim-
inished in its DNA-binding capacity (5,12). We have been
unable to address this issue because our antisera against
TFIIIC110 are unable to block or supershift in an EMSA.
Our study has speciﬁcally examined the hypothesis that
selective induction of TFIIIC110 is a signiﬁcant regulatory
mechanism in vivo.
Figure 6. Immunofluorescence analysis of the subcellular distribution of HA-
TFIIIC110 and HA-Brf1. Left panels show the localization of HA antigen in
cells stably transfected with pTRE2hygHA-TFIIIC110 (A) or pTRE2hygHA-
Brf1 (B) and cultured without doxycycline (upper panels) or induced with
doxycycline for 48 h (lower panels). Right panels show DAPI staining of the
same cells.
Figure 7. HA-TFIIIC110 associates with other TFIIIC subunits and pol III-
transcribed genes. (A) Western blot using anti-HA antibody of material
immunoprecipitated using preimmune serum (lanes 3 and 4) or antiserum
against TFIIIC220 (lanes 5 and 6), as well as 10% inputs (lanes 1 and 2), from
pTRE2hygHA-TFIIIC110 stably transfected HeLa cells cultured in the
absence (odd-numbered lanes) or presence (even-numbered lanes) of
doxycycline. (B) Proteins immunoprecipitated using monoclonal antibodies
against RB (lanes 1 and 2), HA (lanes 3 and 4) and cyclin D1 (lanes 5 and 6)
from pTRE2hygHA-TFIIIC110 stably transfected HeLa cells cultured in the
absence (odd-numbered lanes) or presence (even-numbered lanes) of
doxycycline were western blotted with antiserum against TFIIIC90. (C)
ChIP assay using pTRE2hygHA-TFIIIC110 stably transfected cells cultured
in the absence or presence of doxycycline, as indicated. Cross-linked
chromatin was immunoprecipitated using antibodies against TBP, TFIIIC110,
HA or TFIIB, or was mock-immunoprecipitated with beads unattached to
antibody, as indicated. Immunoprecipitated material was PCR amplified
using primers to the genes encoding 5S rRNA, tRNA
Leu and TFIIIC220, as
indicated. Input panels show product intensities obtained using 10, 2 and
0.4% of input.
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TFIIIC concerns the identity of TFIIIC1, a TFIIIC-associated
fraction that was found to be required for transcription of
all types of pol III template using partially-puriﬁed reconsti-
tuted systems (36–41). Although candidate components of
TFIIIC1 have been suggested (9,41), the functional signiﬁ-
cance of these polypeptides has not been demonstrated, as
far as we are aware. Indeed, efﬁcient pol III transcription of
a U6 gene has been reconstituted more recently using a com-
bination of recombinant and highly puriﬁed proteins without
any TFIIIC1 fraction (42). It was suggested that TFIIIC1
might in fact correspond to Bdp1, an essential subunit of TFI-
IIB that dissociates readily during puriﬁcation (42). This pos-
sibility is supported by the ﬁnding that Bdp1 co-fractionates
with TFIIIC1 activity and can substitute for TFIIIC1 fractions
in a reconstituted transcription assay (43).
The model of TFIIIC110 induction was proposed as a
mechanism to explain the activation of pol III transcription
by E1A and by serum (5,9,12). We have not examined
whether E1A can selectively stimulate TFIIIC110 expression,
but our data suggest that this would have little impact on
transcriptional output, at least in HeLa cells. Other docu-
mented mechanisms may instead account for pol III activa-
tion under these circumstances. Yoshinaga et al. (16)
demonstrated that overall levels of TFIIIC had increased 4-
to 8-fold 30 h after adenovirus infection of HeLa cells. In
addition, E1A can overcome RB-mediated repression of
pol III transcription, both in vitro and in vivo (20). Serum
stimulation leads to a phosphorylation-mediated inactivation
of RB and so can also derepress the pol III machinery (44).
Furthermore, pol III transcription is directly activated by
c-Myc and Erk, both of which are serum-inducible (33,45).
Combinations of these mechanisms may be sufﬁcient to
explain pol III responsiveness to E1A and to serum.
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